Capricor Therapeutics Inc (NASDAQ:CAPR) Sees Significant Growth in Short Interest

Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) was the recipient of a significant increase in short interest in December. As of December 31st, there was short interest totalling 7,950,000 shares, an increase of 42.2% from the December 15th total of 5,590,000 shares. Based on an average daily trading volume, of 1,670,000 shares, the days-to-cover ratio is presently 4.8 days.

Capricor Therapeutics Trading Up 7.0 %

Shares of CAPR stock traded up $0.88 during trading hours on Wednesday, hitting $13.47. The company's stock had a trading volume of 850,262 shares, compared to its average volume of 929,696. The business has a fifty day moving average of $15.68 and a 200-day moving average of $11.43. Capricor Therapeutics has a twelve month low of $3.52 and a twelve month high of $23.40. The stock has a market cap of $612.48 million, a price-to-earnings ratio of -12.71 and a beta of 4.08.

Institutional Investors Weigh In On Capricor Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Point72 Asset Management L.P. acquired a new stake in shares of Capricor Therapeutics during the third quarter valued at $3,806,000. PFM Health Sciences LP purchased a new position in Capricor Therapeutics in the 3rd quarter valued at about $2,324,000. State Street Corp lifted its holdings in Capricor Therapeutics by 27.8% in the 3rd quarter. State Street Corp now owns 512,313 shares of the biotechnology company's stock valued at $7,792,000 after purchasing an additional 111,291 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Capricor Therapeutics during the 2nd quarter worth about $426,000. Finally, Renaissance Technologies LLC grew its holdings in shares of Capricor Therapeutics by 158.7% during the second quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company's stock worth $656,000 after buying an additional 84,350 shares in the last quarter. Hedge funds and other institutional investors own 21.68% of the company's stock.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Cantor Fitzgerald increased their price objective on Capricor Therapeutics from $25.00 to $30.00 and gave the stock an "overweight" rating in a research report on Thursday, November 14th. Maxim Group boosted their price objective on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the stock a "buy" rating in a report on Wednesday, September 25th. Piper Sandler began coverage on shares of Capricor Therapeutics in a research report on Monday, October 21st. They set an "overweight" rating and a $35.00 target price on the stock. HC Wainwright reiterated a "buy" rating and set a $77.00 price target on shares of Capricor Therapeutics in a research report on Thursday, January 2nd. Finally, Oppenheimer restated an "outperform" rating and issued a $15.00 price target on shares of Capricor Therapeutics in a report on Monday, September 23rd. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $34.50.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.